Fatigue in newly diagnosed acute myeloid leukaemia: general population comparison and predictive factors.

"Competing Interests: ACa: advisory board participation and consultancy: Celgene, Janssen, Merck, Novartis, Gilead, Pfizer, Jazz, Amgen.AT: Grants: Celgene, Roche, Novartis, Abbvie, outside the submitted workDC: president of FACIT.org.FE: personal fees from Abbvie, Janssen, Orsenix, Takeda, and grants and personal fees from Amgen, outside the submitted work;ML: Advisory Boards: Celgene, Abbvie, Gilead Sci, Novartis, Daiichi Sankyo, MSD Sanofi; outside the submitted workMPM: Advisory Board and Speaker Bureau: Novartis, Astellas, Jazz Pharmaceuticals, Amgen, Abbvie, Janssen; Advisory Board: Celgene, Pfizer, outside the submitted work.MV: personal fees from Amgen, Millennium Pharmaceuticals Inc., Celgene, Janssen, Novartis and Incyte.All other authors have no conflicts of interest to disclose. "

"Funding: This work was in part supported by the Associazione Italiana contro le Leucemie, Linfomi e Mieloma (AIL). The Grant number is not available as the “AIL” is a non-profit, charity organization which partly funded the original clinical trial. Author LBO was supported by a National Institutes of Health, National Cancer Institute training grant at the time this work was completed (T32CA193193)."